Release Date: February 26, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

CareDx Inc (NASDAQ:CDNA) reported a 32% year-over-year increase in quarterly revenue, reaching $86.6 million. The company achieved $9.8 million in adjusted EBITA in the fourth quarter and $27.8 million for the full year. CareDx Inc (NASDAQ:CDNA) ended the year with a strong cash balance of $261 million and no debt. Testing services revenue grew by 37% year over year, with a 14% increase in test volumes. The company expanded payer coverage significantly, adding millions of new commercial covered lives for its products.

Negative Points

The company anticipates some seasonality in testing volumes, with modest growth expected in the first quarter of 2025. CareDx Inc (NASDAQ:CDNA) faces potential challenges in ASP growth, with a cautious outlook on ASP appreciation. The company is not including contributions from prior period collections in its 2025 guidance, which could impact revenue expectations. There is uncertainty regarding the impact of new product launches on gross margins, particularly for smaller indications. CareDx Inc (NASDAQ:CDNA) anticipates potential appeals in ongoing IP litigation, which could affect future financials.

Q & A Highlights

Warning! GuruFocus has detected 6 Warning Signs with CDNA.

Q: Can you talk about your efforts in converting existing accounts with less than three solutions to three or more solutions, versus acquiring new customer accounts? A: John Hanna, CEO: We are focused on our Zin coffee product for quality reporting and dashboarding, which helps kidney transplant centers monitor their performance. Additionally, we are launching a medication therapy management program to assist patients with drug interactions. These solutions are synergistic and will drive the use of Allosure across kidney, heart, and lung. Our commercial team is focused on selling our total portfolio of solutions into each account, which will be a catalyst for growth in 2025.

Q: Can you talk about the impact on ASPs from launching tests like Allosure Heart for pediatric patients and Allosure Kidney for simultaneous kidney and pancreas transplantation? A: John Hanna, CEO: These indications are smaller but important. We anticipate being paid on these claims consistent with other commercial claims for Allosure Heart and Kidney. We do not expect these launches to negatively or positively impact gross margins for 2025.

Q: With the reversal of the $96 million litigation verdict, how are you thinking about capital allocation, including buybacks and M&A? A: John Hanna, CEO: We anticipate the litigation may be appealed, but having the patents invalidated is significant. Our capital allocation strategy remains unchanged: reinvest in the business, look for strategic opportunities in the transplant field, and consider share buybacks if no other opportunities arise.

Story Continues

Q: Can you clarify the contribution of prior period collections in Q4 and the full year 2024, and is there any contribution expected in 2025 guidance? A: Abhichek Jane, CFO: Q4 revenue includes $2.2 million from tests outside of Q4, and for 2024, we recognized $17 million from tests prior to 2024. Our 2025 guidance does not include contributions from these one-time tests, which presents an upside opportunity.

Q: How do you view the ROI of new hires, particularly in terms of ASP and revenue capture improvements? A: Abhichek Jane, CFO: We anticipate ASPs to grow in the low single digits. We have brought in new leadership and are improving our revenue cycle management systems, which presents an opportunity for ASP growth. We are cautious in our guidance but see potential for improvement as these initiatives take effect.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments